Safety under the regulatory spotlight — 206 documents in 90 days

95 documents in the last 30 days alone

This concentration of regulatory activity around safety may indicate a tightening cycle, particularly if the recent documents are emphasizing new expectations for signal detection, risk mitigation, or post-market surveillance rather than clarifying existing norms. Sponsors should consider that regulators may be increasing scrutiny on benefit-risk narratives and the timeliness of safety data flow, and they should watch for shifts in pharmacovigilance guidance, class-wide safety communications, and any emerging expectations around real-world evidence integration.